RUO Disclaimer: All QRM products are strictly for in vitro laboratory and research use only by qualified researchers in appropriate facilities. Nothing here implies, suggests, or recommends any diagnostic, therapeutic, or clinical application or use in humans or animals.
- SSL Secured
- Secure Checkout
- Guaranteed Delivery
- Third-Party Tested
Tesamorelin
A stabilized analog of growth hormone releasing hormone (GHRH) with an extensive peer-reviewed research record, including one of the few GH-related compounds studied in formal clinical trial models. A benchmark compound for GHRH pathway research.
$80.00
- +99% Purity
- Third-Party Tested
- COA Available
- SSL Secured
- Secure Checkout
- Guaranteed Delivery
- Third-Party Tested
A stabilized analog of growth hormone releasing hormone (GHRH) with an extensive peer-reviewed research record, including one of the few GH-related compounds studied in formal clinical trial models. A benchmark compound for GHRH pathway research.
About Tesamorelin
Tesamorelin is a stabilized synthetic form of growth hormone-releasing hormone (GHRH), engineered to resist rapid degradation and maintain targeted research activity. Endogenous GHRH is produced by the hypothalamus and acts on pituitary receptors that trigger the synthesis and release of growth hormone. By mimicking this signal with a more stable analogue, researchers have been able to study the effects of sustained GHRH receptor activation on growth hormone output and its downstream effects in controlled, in vitro research settings.
What distinguishes Tesamorelin from other growth hormone-related research compounds is its mechanism of action. Rather than directly introducing growth hormone or bypassing the pituitary receptor pathway entirely, Tesamorelin works upstream, activating the hypothalamic-pituitary signaling axis through its native receptor target. Researchers have studied this approach for its potential to produce growth hormone responses that reflect the pulsatile release patterns associated with endogenous GHRH receptor activation, considered relevant to characterizing downstream growth hormone signaling in vitro.
Tesamorelin has also attracted research interest for its studied effects on adipose tissue distribution and for emerging research into its potential effects on neurological pathways. In vitro and controlled research models have examined its effects on fat accumulation associated with growth hormone deficiency, while separate lines of investigation have explored its potential relevance to cognitive function and neurodegenerative signaling, giving Tesamorelin an unusually broad research profile across metabolic and neurological endpoints.
Mechanism of Action
Tesamorelin has been investigated in experimental models for its action on endocrine and metabolic pathways:
- Tesamorelin has been studied for its binding to GHRH receptors on pituitary cells, an interaction that stimulates the synthesis and pulsatile release of growth hormone. Research has examined whether Tesamorelin’s engineered stability allows it to sustain this signaling more effectively than native GHRH, and whether that sustained activity translates to more robust growth hormone output in research models.
- Studies have examined Tesamorelin’s downstream effects on IGF-1, the primary mediator of growth hormone signaling at the cellular level. IGF-1 is produced in response to growth hormone stimulation and governs a range of downstream pathway activity including adipose regulation and cellular turnover. Investigators have studied changes in IGF-1 as a key marker of Tesamorelin’s biological activity across research contexts.
- Tesamorelin has been investigated for its effects on adipose tissue metabolism. Growth hormone plays an active role in regulating how fat is stored and mobilized at the cellular level, and research has examined whether Tesamorelin-driven growth hormone stimulation produces measurable changes in adipose accumulation patterns in growth hormone-deficient research models.
- Research has examined Tesamorelin’s potential effects on neurological signaling pathways, with studies investigating its activity in models relevant to cognitive function and neurodegenerative processes. Investigators have studied whether growth hormone and IGF-1 signaling in neural tissue contributes to the regulation of cognitive pathway markers, with Tesamorelin used as a tool for examining this relationship in vitro.
- Tesamorelin has been studied for its effects on lipid-related signaling markers, with research examining changes in lipid metabolism indicators in growth hormone-deficient models. Investigators have studied these effects in the context of the well-documented relationship between growth hormone pathway activity and lipid metabolism dysregulation.
Research Highlights
Tesamorelin has been extensively studied for its ability to stimulate growth hormone release through the hypothalamic-pituitary signaling pathway. Research has examined its effects on growth hormone pulse amplitude and frequency, with studies reporting measurable changes in growth hormone and IGF-1 levels across controlled research contexts. Its upstream mechanism of action makes it a useful tool for investigators studying growth hormone axis activity while preserving physiologically consistent hormone release patterns.
One of the most studied applications of Tesamorelin involves its effects on adipose tissue accumulation in growth hormone-deficient research models. Research has examined its potential to influence fat distribution patterns at the cellular level, with investigators attributing observed changes to growth hormone-mediated shifts in adipose metabolism. These findings position Tesamorelin as a relevant compound for researchers studying the metabolic consequences of growth hormone pathway dysregulation.
Tesamorelin has been studied for its effects on lipid metabolism markers and related signaling indicators in growth hormone-deficient research models. Research has examined changes in triglyceride levels and other metabolic readouts in structured research environments, with investigators contextualizing these effects within the broader relationship between growth hormone pathway activity and lipid metabolism dysregulation.
Studies have examined Tesamorelin's effects on IGF-1 as a primary readout of growth hormone axis activity in vitro. Research has reported consistent changes in IGF-1 levels across Tesamorelin research models, with investigators studying the relationship between IGF-1 elevation and downstream adipose, metabolic, and cellular signaling effects.
Product Specifications
- Molecular Formula
- C₂₂₁H₃₆₆N₇₂O₆₇S
- Molecular Weight
- 5,135.77 g/mol
- CAS #
- 218949-48-5
- Sequence
- Trans-3-hexenoic acid-Tyr-Ala-Asp-Ala-Ile-Phe-Thr-Asn-Ser-Tyr-Arg-Lys-Val-Leu-Gly-Gln-Leu-Ser-Ala-Arg-Lys-Leu-Leu-Gln-Asp-Ile-Met-Ser-Arg-Gln-Gln-Gly-Glu-Ser-Asn-Gln-Glu-Arg-Gly-Ala-Arg-Ala-Arg-Leu-NH₂
- Purity
- ≥99% (HPLC verified)
- Form
- Lyophilized powder
- Appearance
- White to off-white powder
- Solubility
- Universal Solvent
- Storage
- -20°C (lyophilized), 2-8°C (reconstituted)
Reference
References
- Falutz, J., Allas, S., Blot, K., et al. (2007). Metabolic effects of a growth hormone-releasing factor in patients with HIV. New England Journal of Medicine, 357(23), 2359–2370.
- Stanley, T. L., Falutz, J., Mamputu, J. C., et al. (2012). Effects of tesamorelin on non-alcoholic fatty liver disease in HIV-infected patients with abdominal fat accumulation. AIDS, 26(18), 2counter–2373.
- Baker, L. D., Barsness, S. M., Borson, S., et al. (2012). Effects of growth hormone-releasing hormone on cognitive function in adults with mild cognitive impairment and healthy older adults. Archives of Neurology, 69(11), 1420–1429.
